2005
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction
Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005, 19: 1635-1641. PMID: 16184033, DOI: 10.1097/01.aids.0000183628.20041.f2.Peer-Reviewed Original ResearchConceptsOpiate withdrawalPharmacokinetic interactionsChronic methadone therapyDaily protease inhibitorEffect of atazanavirIsomers of methadonePlasma maximal concentrationPlasma trough concentrationsEffective antiretroviral treatmentRelevant pharmacokinetic interactionsSteady-state pharmacokineticsConcentration-time curveSubstance abuse treatmentHIV diseaseTrough concentrationsAntiretroviral treatmentHIV infectionMethadone therapyDaily administrationDosage adjustmentAntiretroviral drugsBioequivalence rangePharmacological interactionsPlasma concentrationsRelevant symptoms
2002
The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects
Rainey PM, Friedland GH, Snidow JW, McCance‐Katz E, Mitchell SM, Andrews L, Lane B, Jatlow P. The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects. American Journal On Addictions 2002, 11: 66-74. PMID: 11876585, DOI: 10.1080/10550490252801657.Peer-Reviewed Original ResearchConceptsSerum concentrationsCombination tabletSerum concentration-time curveMethadone dose changesMethadone serum concentrationsMaximum serum concentrationOpiate-dependent subjectsConcentration-time curveVolume of distributionCombination pharmacotherapyMethadone pharmacokineticsTerminal eliminationCo-administrationDose changesMean areaSignificant differencesPharmacokineticsSubjectsSubject studyHIVPharmacotherapyPatientsAdministration